866-997-4948(US-Canada Toll Free)

Amyloidosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Published By :

Transparency Market Research

Category :

Healthcare IT

Amyloid is an abnormal protein produced in the bone marrow. Amyloidosis is a rare disease caused by extracellular and intracellular deposition of amyloid which alters the normal activities of the tissue. Commonly affected organs by amyloidosis encompass kidney, heart, nervous system, digestive tract, liver and spleen. Severe form of amyloidosis in later stages can lead to permanent organ failure and in extreme cases can be life-threatening also. There are over 30 different types of amyloid proteins discovered so far and treatment can only help in managing the symptoms and regulating the production of amyloid protein and not the permanent cure. About 90% of the amyloid formed due to the aggregation of misfolded proteins whereas, 10% of amyloidosis is due to presence of components such as apolipoprotein-E (apoE), glycosaminoglycans (GAGs) and serum amyloid P-component (SAP). According to American Society of Hematology the prevalence rate of amyloidosis in the United States is approximately 1 in 90,666 of which 60 – 65 % of the patient are men. Prominent symptoms of the disease include fatigue, weight loss, breathlessness, peripheral oedema, carpal tunnel syndrome, postural hypotension and sensory change. In the United Kingdom systemic amyloidosis is responsible for approximately one in 1,200 deaths each year.   

Amyloidosis can be broadly classified into 3 major categories namely AA amyloidosis, AL amyloidosis and Transthyretin amyloidosis. In general amyloidoses are generally denoted by a capital “A” signifying the amyloid present followed by an abbreviation for the fibril protein. AA amyloidosis is a normal sequence serum amyloid - A protein produced mainly in the liver in response to multiple cytokines. AA mostly occur in various chronic inflammatory disorders and is one of the most common systemic amyloidosis across the globe. Some of the conditions associated with AA include: rheumatoid arthritis, alzheimer disease, psoriasis, tuberculosis, renal cell carcinoma, hodgkin disease and non-hodgkin lymphoma.

 AL amyloidosis or light chain amyloidosis monoclonal plasma cell disorder closely related to multiple myeloma. Organs involved in the AL amyloidosis include heart, kidney, peripheral nerve, gastrointestinal tract, respiratory tract and other organs. Treatment for AL amyloidosis in most instances is similar to multiple myeloma i.e. chemotherapy. Selected patient are treated with high-dose melphalan and autologous stem-cell transplantation. Alternative therapy includes rituximab, etanercept, thalidomide, iododoxorubicin and lenalidomide. In about about 80% the cases AA amyloidosis is fetal with median survival rate of 1-2 years only. Transthyretin amyloidosis (ATTR) is one of the most frequent inherited systemic forms of amyloidosis. ATTR is an autosomal-dominant disease but is associated with at least 100 different transthyretin mutations. Other forms of amyloidosis include heavy-chain amyloidosis, beta2 -microglobulin amyloidosis, hereditary renal amyloidosis and Central nervous system amyloidosis.

Major drivers for the growth of the global amyloidosis market include favourable investment and reimbursement facilities in developed economic countries. On the other hand high cost involved in treatment and limited awareness may hinder the growth of the overall market. Biopsy is the widely accepted diagnostic tool for amyloidosis and in about two-third of the patient alkylator-based chemotherapy is effective in managing amyloidosis. Noninvasive tests such as echocardiography of the heart and X-ray of bone abnormalities may provide supportive information but are not sufficient for the diagnosis of amyloidosis. Some of the prominent players operating in global amyloidosis market include Pfizer Inc., GlaxoSmithKline plc, Celgene Corporation, Alnylam Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Prothena Corporation plc. Premier institutes and universities promoting the development of amyloidosis clinical trial studies include Stanford University, Boston University, IRCCS Policlinico San Matte and Umea University.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market      

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Please fill the Request TOC form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *